What is ImmuCell?
ImmuCell Corporation is dedicated to developing and marketing scientifically validated products aimed at enhancing the health and productivity of dairy and beef cattle. The company's flagship product, First Defense®, provides immediate immunity to newborn calves. ImmuCell is also advancing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows that offers an alternative to traditional antibiotics by eliminating the need for milk discard. This focus on practical, science-based solutions positions ImmuCell as a key player in the veterinary pharmaceutical market.
How much funding has ImmuCell raised?
ImmuCell has raised a total of $32.6M across 8 funding rounds:
Stock Offering
$5.9M
Share Placement
$3.5M
Multiple Rounds
$10.3M
Stock Offering
$8.3M
Debt
$350K
Share Placement
$4.3M
Stock Issuance/Offering (2016): $5.9M with participation from Undisclosed
Share Placement (2016): $3.5M led by Undisclosed
Debt (2017): $6.5M supported by TD Bank N.A
Private Equity (2017): $1.1M featuring Brian L. Pessin and Sandra F. Pessin
Stock Issuance/Offering (2017): $2.7M backed by Craig-Hallum Capital Group
Stock Issuance/Offering (2019): $8.3M with participation from Craig-Hallum Capital Group
Debt (2020): $350K led by PPP
Share Placement (2021): $4.3M, investors not publicly disclosed
Key Investors in ImmuCell
TD Bank N.A
TD Bank N.A. is a major financial institution that likely provided debt financing, supporting ImmuCell's operational and capital expenditure needs.
Craig-Hallum Capital Group
Craig-Hallum Capital Group is an investment banking firm that has participated in ImmuCell's stock offerings, indicating their role in facilitating equity financing and capital raising activities.
Brian L. Pessin
Brian L. Pessin, alongside Sandra F. Pessin, participated in a private equity round, suggesting a direct investment in ImmuCell's growth and strategic initiatives.
What's next for ImmuCell?
The recent major strategic investment in ImmuCell Corporation is expected to accelerate the development and commercialization of its innovative product pipeline, particularly Re-Tain®. This capital infusion will likely support expanded research and development efforts, enhance manufacturing capabilities, and bolster market penetration strategies. ImmuCell's commitment to providing antibiotic alternatives and immediate immunity solutions aligns with growing industry demands for sustainable and effective animal health management, positioning the company for sustained growth and market leadership.
See full ImmuCell company page
